Novartis Neoral Labeling Must Drop "Microemulsion" Descriptor, FDA Says
Executive Summary
Novartis Neoral cyclosporine "for microemulsion" is not a unique dosage form, FDA maintained in its Nov. 2 response denying citizen petitions submitted to the agency by the company seeking to block approval of a generic version of Neoral.
You may also be interested in...
FDA Review Standards “Inconsistent” For New Drugs, Generics, PhRMA Says
The lack of an integrated review staff for new drugs and generics has led to "inconsistent" review standards between new drug divisions and the Office of Generic Drugs, the Pharmaceutical Research & Manufacturers of America says in a "white paper" submitted to FDA
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials